Plain-English definitions for the acronyms, methods and frameworks our teams actually use, written by people who file the dossiers, not pulled from a textbook.
Accelerated approval is a regulatory pathway that allows earlier market access for therapies that address serious conditions and fill an unmet medical need based on surrogate endpoints.
The addressable population is the subset of patients within a broader disease area who meet specific criteria for treatment with a given product or intervention.
An advisory board is a structured meeting where external experts provide insights to support strategic, clinical, or scientific decision-making in pharmaceutical development.
Artificial intelligence (AI) refers to computer systems designed to perform tasks that typically require human intelligence, such as learning, reasoning, and decision-making.
An asset evaluation establishes the attractiveness, market potential and likelihood of success for an internal or external asset.
Attribution refers to the process of linking a scientific, clinical, or strategic outcome to a specific source, action, or stakeholder, ensuring transparency and traceability.
Benefit-risk assessment is the structured evaluation of a treatment’s positive therapeutic effects against its potential risks, informing regulatory and clinical decisions.
Bibliometrics refers to the quantitative analysis of academic publications used to evaluate research performance and influence.
A biosimilar is a biologic medicine that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or efficacy.
In market access and regulatory contexts, burden of proof refers to the obligation of pharmaceutical companies to demonstrate the value, efficacy, and safety of their products to key stakeholders.
Channel strategy refers to how pharmaceutical companies engage different communication and access pathways to reach key stakeholders across medical, payer, and patient channels.
Clinical benefit refers to the positive impact a treatment has on patient health, including symptom relief, disease modification, or survival improvement.
Clinical development is the systematic process of testing a new medical intervention in humans to establish its safety and efficacy.
Clinical differentiation is the degree to which a product stands out from alternatives based on its therapeutic profile, safety, or ease of use.
The clinical landscape refers to the current state of clinical development activity within a specific disease area, including ongoing and completed trials, treatment approaches, and emerging standards of care.
Clinical meaningfulness describes the real-world relevance of a treatment’s effects on outcomes that matter to patients, providers, and payers.
A collaboration network is a visual or analytical representation of co-authorship and institutional relationships within scientific research communities.
Comparative effectiveness assesses how two or more interventions perform relative to each other for a defined patient population, using direct trials, indirect comparisons or real-world studies.
The competitive landscape refers to the current set of products, companies, and strategies competing within a specific therapeutic area, market, or indication.
The conference landscape refers to the network of scientific and medical meetings where new clinical data, research, and strategic priorities are presented and discussed.
Conference planning is the strategic coordination of a pharmaceutical company’s activities before, during, and after a scientific or medical meeting to maximize scientific impact and stakeholder engagement.
A decentralized clinical trial (DCT) is a study that uses digital tools and remote methods to reduce or eliminate the need for in-person site visits.
A development pipeline is the collection of drug or therapy projects that a company, disease area or industry has in discovery and development at a given time, from early research to possible market approval.
Digital activity refers to the online engagement of stakeholders across platforms such as social media, webinars, and digital conferences, providing insights into their interests, influence, and network.
The digital landscape refers to the network of online platforms, behaviors, and content shaping scientific dialogue, stakeholder engagement, and perception within a therapeutic area.
Digital listening is the continuous monitoring and analysis of online conversations to capture insights on stakeholder perspectives, emerging topics, and perceptions of scientific data.
A DOL is an influential person or organization with a large online presence, often on social media, in the healthcare or pharmaceutical industry.
Digital transformation is the integration of digital technologies into core pharmaceutical operations to enhance scientific, clinical, and commercial performance.
Disease burden refers to the total impact of a health condition on individuals, healthcare systems, and society, including clinical, economic, and quality-of-life dimensions.
Disease severity refers to the extent or intensity of a condition’s impact on a patient’s health, functioning, and quality of life.
Dose optimization is the process of identifying the most effective and safe drug dose for a specific patient population.
An early access program (EAP) allows patients with serious or life-threatening conditions to access investigational therapies prior to full regulatory approval.
Eligibility criteria are the inclusion and exclusion rules that define which participants can enroll in a clinical trial.
Engagement planning is the strategic design of how and when to interact with external stakeholders to support scientific, clinical, and commercial goals.
Epidemiology is the study of the distribution, patterns and determinants of health across defined populations.
An evidence-generation program is a coordinated plan for producing clinical, real-world, and economic data to support the value and positioning of a pharmaceutical product.
An evidence hierarchy is a ranked framework that classifies types of evidence based on their methodological rigor and reliability.
An external control arm uses data from outside a clinical trial to serve as a comparator for evaluating a treatment’s effectiveness.
Feasibility planning is the process of evaluating whether a clinical trial or development strategy can be successfully executed based on operational, scientific, and market factors.
First-author refers to the person listed first on a scientific publication and generally recognised as its primary contributor. The status can indicate research leadership but should be interpreted alongside contribution statements and disciplinary conventions.
Formulary inclusion is the decision by a healthcare payer or institution to list a pharmaceutical product as an approved treatment option.
Gap analysis identifies missing evidence, insights, alignment or capabilities by comparing the current position with defined strategic, regulatory or stakeholder requirements.
A generic is a medication that is chemically identical to an approved brand-name drug and intended to offer the same clinical benefit at a lower cost.
A global value dossier (GVD) is the central evidence document a manufacturer builds so local teams can make a consistent case for a product's value to payers and HTA bodies.
A health economic model is a structured tool used to estimate the costs and outcomes associated with a healthcare intervention over time.
HEOR is the discipline focused on evaluating the economic value, clinical outcomes, and humanistic impact of healthcare interventions to inform decision-making.
A health technology assessment (HTA) is a systematic evaluation of the clinical, social, economic and ethical implications of a new medical intervention or technology.
An HEOR stakeholder is an individual or organisation that uses, assesses or influences health economics and outcomes research to guide reimbursement, policy, coverage or treatment adoption.
An HTA submission is a formal package of clinical, economic and wider evidence provided to an assessment body to support reimbursement, funding or formulary decisions.
An impact factor is a bibliometric score VISFO uses to rank the influence of an expert — whether a key opinion leader, digital opinion leader, key clinical investigator, payer-influencing expert, rising star or co-author — using publication volume, journal quality, authorship position and citation reach.
Implementation science studies how evidence-based therapies, guidelines and practices are adopted, delivered and sustained in real-world healthcare settings.
Disease incidence is the occurrence of new cases in a defined population over a specified period. It can be measured as cumulative incidence or as a rate based on person-time at risk.
Inclusion and exclusion criteria define who can or cannot participate in a clinical trial, based on factors like disease state, age, comorbidities, or prior treatment.
An indication is the specific disease, condition, symptom or patient setting for which a treatment or intervention is approved or authorised.
An indication assessment is the strategic evaluation of market opportunities within multiple potential indications to determine which to prioritize for development and launch, and maximize the commercial success of a new product or medical device.
Institutional affiliation is the academic, research, clinical or healthcare organisation with which a professional is formally associated. It provides context for their work, networks and potential influence.
An integrated evidence plan (IEP) outlines the coordinated generation of clinical, economic, and real-world data to support a product’s lifecycle strategy.
Internal buy-in is cross-functional agreement and practical support for a strategic decision, investment or action plan within a pharmaceutical organisation.
An investigator-initiated study (IIS) is a clinical or scientific study developed and led by an independent researcher, often supported by pharmaceutical funding or materials.
A Key Clinical Investigator (KCI) is a highly experienced healthcare professional with a proven track record in conducting successful clinical trials.
A Key Opinion Leader (KOL) is a highly influential and respected expert in their field who shapes opinions and decisioning.
Key Opinion Leader (KOL) mapping is the process of identifying and analyzing key opinion leaders based on their influence, expertise, and relevance to a specific therapeutic area or strategy.
Launch sequence optimization is a strategic process that determines the best order and timing for launching a new drug across different markets.
Lifecycle evidence generation is the strategic planning and execution of data generation activities throughout a product’s development, launch, and post-market phases.
Line of therapy refers to the sequence in which treatments are given to a patient, typically categorized as first-line, second-line, or third-line based on clinical guidelines or treatment history.
A literature library is a curated collection of publications relevant to a specific individual, topic, or strategy, used to support insight generation and engagement planning.
Market Access is a function within pharmaceutical and biotechnology companies ensuring that the patients most likely to benefit from a new drug can access it, and that the drug is both cost-effective for healthcare systems and commercially viable for the manufacturer.
A Market Access Key Opinion Leader (MAKOL) is a recognized expert who regularly publishes on market access themes, for example, disease burden, treatment cost-effectiveness and reimbursement challenges, within a specific therapeutic area.
Market conditioning is the strategic process of shaping stakeholder awareness, perceptions, and expectations ahead of product launch or clinical milestone.
Market potential is the estimated maximum revenue opportunity for a pharmaceutical product within a defined population, therapeutic area, or geography.
Market shaping is the deliberate effort to influence how a disease or treatment category is understood and managed by changing evidence, care pathways, stakeholder expectations or access conditions.
Market value refers to the current or projected financial worth of a pharmaceutical product or therapeutic area based on real-world sales, pricing, and market dynamics.
Medical Affairs communicates scientific evidence to healthcare professionals, payers and policymakers, while bringing external insights back into strategy to support the safe and effective use of treatments.
Medical insight capture is the process of collecting, analyzing, and synthesizing insights from healthcare professionals to inform strategy and decision-making.
A Medical Science Liaison (MSL) is a scientific expert who engages with healthcare professionals to communicate clinical data and gather insights that inform medical and commercial strategy.
Medical strategy is the plan that guides how scientific and clinical knowledge is generated, interpreted, and communicated throughout a product’s lifecycle.
Morbidity rate is a measure of how frequently a disease or health condition occurs within a specific population over a defined period of time.
Mortality rate is a measure of the frequency of death in a defined population over a specified period, often used to assess the severity or impact of a disease.
Multi-stakeholder engagement refers to the coordinated interaction with diverse healthcare decision-makers, including providers, payers, regulators, and patient advocates.
Multiplicity refers to the increased risk of false-positive results when multiple statistical tests are performed in a clinical trial.
A patient advocacy group is an organization that represents the interests of individuals affected by a particular disease or condition, often influencing research, policy, and access.
Patient engagement is the active involvement of patients in the design, development, and evaluation of healthcare strategies, including clinical trials and evidence generation.
Patient-reported outcomes are direct reports from patients about their symptoms, functioning, quality of life or treatment experience, without interpretation by clinicians.
A Payer Influencing Key Opinion Leader (PIKOL) is a key influencer of healthcare policy and reimbursement decisions.
Peer-to-peer engagement is non-promotional interaction between medical professionals that supports scientific education, evidence sharing and clinical discussion, often facilitated by field medical teams.
Pharmacovigilance is the science and practice of monitoring, detecting, assessing, and preventing adverse effects or other drug-related problems after a product has entered the market.
A placebo-controlled study is a clinical trial in which the effects of an investigational treatment are compared against an inactive substance that mimics the treatment but has no therapeutic effect.
Population health impact is the measurable or projected effect of a therapy or strategy on disease burden, healthcare use, morbidity or mortality across a defined population.
Predictive analytics uses statistical models and machine learning to forecast outcomes such as patient response, trial performance, market uptake and access challenges, helping pharma teams plan under uncertainty.
Prevalence is the proportion of a defined population that has a disease at a specified point in time. It supports disease-burden analysis, population forecasting and access planning.
Price benchmarking is the process of comparing the price of a pharmaceutical product to similar therapies across markets to inform pricing strategy and negotiation.
Price potential refers to the estimated price a pharmaceutical product could reasonably achieve based on its clinical value, competitive positioning, and payer willingness to pay.
Pricing and reimbursement refers to the processes by which a pharmaceutical product is assigned a price and granted coverage or funding by healthcare payers.
Product value communication is the strategic process of articulating the unique attributes, patient benefits, and economic value of a drug or therapy.
A publication strategy is a structured plan for disseminating scientific and clinical data through peer-reviewed journals and congresses to support a product’s development and value story.
Publication type categorizes scientific articles by format and purpose, influencing how they are perceived and weighted in bibliometric analysis.
Qualitative research is a method used to gather non-numerical insights into stakeholder behaviors, perceptions, motivations, and decision-making processes.
Quantitative research involves the collection and statistical analysis of numerical data to identify patterns, test hypotheses, or measure outcomes.
Real-world data (RWD) refers to health-related data collected outside of traditional clinical trials, used to understand how treatments perform in routine clinical practice.
Real-world effectiveness measures how well a treatment performs in routine clinical practice, outside the controlled environment of clinical trials.
Real-world evidence (RWE) refers to clinical insights derived from the analysis of real-world data (RWD), used to evaluate how treatments perform outside of controlled trial settings.
Regulatory strategy defines the pathways, evidence, submissions and authority interactions used to obtain and maintain product authorisation across target markets.
A regulatory submission is the formal dossier sent to a health authority to seek approval for a medicine, indication, formulation or regulated change, supported by quality, safety and efficacy evidence.
The reimbursement landscape comprises the policies, payer requirements, assessment routes and pricing mechanisms that determine whether and how a therapy is funded.
Research and development (R&D) is the process of discovering, designing, and testing new pharmaceutical products to advance medical science and improve patient outcomes.
A Rising Star is a medical or scientific professional in the early to mid-stage of their career who demonstrates potential to become a prominent and influential voice in their field.
A risk factor is any attribute, condition, or behavior that increases the likelihood of developing a disease or experiencing an adverse health outcome.
A risk-sharing agreement is a contract in which a pharmaceutical company and payer share financial or clinical risk according to a treatment’s real-world performance.
Scientific exchange is the transparent, balanced and non-promotional sharing of evidence and medical knowledge between life sciences companies and external stakeholders to support clinical understanding and informed decisions.
Scientific landscaping is the systematic analysis of published and emerging research to identify trends, gaps, and strategic opportunities within a therapeutic area.
Sentiment analysis is the use of natural language processing (NLP) and machine learning to evaluate the tone and emotional context of written or spoken content.
Share of voice (SOV) is a metric that measures the proportion of total mentions or visibility a product, brand, or company receives within a defined competitive or thematic space.
Stakeholder mapping is the creation of a comprehensive overview of key stakeholders relevant to a particular therapeutic area, indication, condition or product.
Stakeholder segmentation is the process of categorizing healthcare stakeholders into groups based on shared attributes, interests, or behaviors to tailor engagement strategies.
Stakeholder sentiment is the perceived tone, attitude or emotional response of healthcare professionals, payers, patients and other influencers towards a product, topic or company.
A surrogate endpoint is a biomarker or intermediate measure used instead of a direct measure of clinical benefit because it is expected to predict that benefit.
A target product profile defines the desired clinical, safety and commercial attributes of a future therapy. It aligns development, regulatory, medical affairs and market access teams on what success should look like.
A thought leader is an individual widely recognized for their expertise, original ideas, and ability to influence thinking and practice within a specific field.
Time-to-peak uptake is the period after launch before a product reaches its highest observed level of prescribing or use in a defined market, indication and population.
The treatment landscape describes current standards of care, approved and emerging therapies, treatment sequencing, clinical practice and unmet needs within a defined disease area.
Trial site analysis is the evaluation of potential clinical trial sites to optimize study performance.
Unbranded engagement provides balanced scientific or educational communication about a disease, unmet need or treatment approach without promoting a specific product.
Unmet need refers to a gap in medical care where current treatment options are inadequate, unavailable, or ineffective for a specific patient population or condition.
A value proposition is an evidence-based summary of a product’s clinical, economic and humanistic benefits, explaining how it addresses unmet need, improves outcomes and justifies its price.
Voice of the customer (VoC) is a structured approach to gathering and analysing stakeholder needs, expectations, experiences and behaviours to inform pharmaceutical decisions.
Willingness to pay refers to the maximum amount a healthcare payer, provider, or system is prepared to spend for a treatment, based on its perceived value and health outcomes.
Workflow integration refers to the alignment of a product or tool with the routines and systems used by healthcare professionals in clinical practice.
The glossary is living. If you spot a gap, an outdated definition or want a worked example, tell us and we'll add it.